This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

November 6–8, 2023 | Munich, GermanyNovember 14–15, 2023 | Digital Partnering



NH TherAguix, located near Grenoble, France, is a Phase 2clinical stage biotechnology company developing AGuIX® radiosensitizing nanoparticles that increase the effectiveness of radiotherapy (RT). 60% of cancer patients will undergo a RT treatment. Designed to increase the dose differential between tumours and healthy tissues, AGuIX® also allows more accurate RT imaging guidance. The combination of these three properties (targeting, imaging and treatment) paves the way for a new generation of precision radiotherapy.

AGuIX® has first been extensively tested in various preclinical models and the results published in high impact publications (>80 papers). The innovation is protected by 15 patent families.

The company has now started its clinical development and as of today the product has been injected in >100 patients with no safety issues. Results of the First In Human Phase I trial (NANORAD1, 15 pts/15, France) so far have confirmed the triple effect : targeting, imaging and treatment (Verry et al, Science Advances 2020, Verry et al. Radiotherapy & Oncology, 2021).

AGuIX® is currently undergoing 2 Ph II randomized trials in brain metastasis using either whole brain radiation therapy, (NANORAD2, 75 pts/100, 12 centers, Grenoble, France) or stereo-radiosurgery, (NANOBRAINMETS, 31 pts/134, Dana Farber Cancer Institute, Harvard, USA). Besides confirmed good tolerance and MRI contrast uptake.

NANORAD2 interim report and preliminary results (67 evaluable patients) show very encouraging signal, both on PFS and OS clinical criteria, that is very promising when comparing the active arm to the control arm with a Hazard Ratio at 0,6. Those results are disclosable under NDA.

In parallel, 3 other Proof of Concept trials are underway to determine AGuIX® efficacy and safety profile, with significant news flow to be delivered Q4-23/Q1-24, beyond results about brain metastasis;

· a Phase Ib-II trial for pancreatic and lung cancers (NANOSMART, 19 pats/100, Dana Farber Cancer Institute, Harvard, USA)

· a Phase Ib-II trial for glioblastoma (NANOGBM, 3 pts/66, multicentric, Clermont Ferrand, France)

· a Phase Ib trial for advanced cervix cancer (NANOCOL, 12 pts/12, Gustave Roussy, France)

NH TherAguix is looking for a ~€40-50M B series to prepare/start sponsored clinical trials aiming at registration, in selected indications, with a focus on neuro-oncology (brain metastasis and glioblastoma).

History of the company

NH TherAguix was founded in 2015 by two scientists, Géraldine Le Duc (CEO of NH TherAguix since inception) and Pr. Olivier Tillement (Chemist at University of Lyon) after 10 years of academic research that led to the invention of AGuIX and the discovery of its radiosensitizing effect. Altogether, NH TherAguix raised €29M of dilutive and non-dilutive funds, including a €13M A series in 2019, led by Bpifrance with Arbevel, Omnes and Supernova. The management team is